Homology modelling of CYP3A4 from the CYP2C5 crystallographic template: analysis of typical CYP3A4 substrate interactions

Reference

• ATKINS, W. M., WANG, R. W. and Lu, A. Y. H., 2001, Allosteric behaviour in cytochrome P450-dependent in vitro drug—drug interactions: a prospective based on conformational dynamics. Chemical Research in Toxicology, 14, 338–347.
   PubMed Web of Science ®Google Scholar
• CHRISTENSEN, I. T. and JoRGENsEN, F. S., 1997, Molecular mechanics calculations of proteins: comparison of different energy minimization strategies. Journal of Biomolecular Structure and Dynamics, 15, 473–487.
   PubMed Web of Science ®Google Scholar
• CONNOLLY, M. L., 1983, Solvent-accessible surfaces of proteins and nucleic acids. Science, 221, 709–713.
   PubMed Web of Science ®Google Scholar
• DE GROOT, M. J. and EKINS, S., 2002, Pharmacophore modeling of cytochromes P450. Advanced Drug Delivery Reviews, 54, 367–383.
   PubMed Web of Science ®Google Scholar
• DE RIENZO, F., FANELLI, F., MENZIANI, C. and DE BENEDETTI, P. G., 2000, Theoretical investigation of substrate specificity for cytochromes P450IA2, P450I1D6 and P45011IA4. Journal of Computer-Aided Molecular Design, 14, 93–116.
   PubMed Web of Science ®Google Scholar
• DOMANSKI, T. L. and HALPERT, J. R., 2001, Analysis of mammalian cytochrome P450 structure and function by site-directed mutagenesis. Current Drug Metabolism, 2, 117–137.
   PubMed Web of Science ®Google Scholar
• DOMANSKI, T. L., HE, Y.-A., HARLOW, G. R. and HALPERT, J. R., 2000, Dual role of human cytochrome P450 3A4 residue Phe-3A4 in substrate specificity and cooperativity. Journal of Pharmacology and Experimental Therapeutics, 293, 585–591.
   Google Scholar
• DOMANSKI, T. L., HE, Y.-A., KHAN, K. K., ROUSSEL, F., WANG, Q. and HALPERT, J. R., 2001, Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and effect on substrate oxidation and cooperativity. Biochemistry, 40, 10150–10160.
   Google Scholar
• DOMANSKI, T. L., Liu, J., HARLOW, G. R. and HALPERT, J. R., 1998, Analysis of four residues within substrate recognition site 4 of human cytochrome P450 3A4: role in steroid hydroxylase activity and cc-napthofiavone stimulation. Archives of Biochemistry and Biophysics, 350, 223–232.
   PubMed Web of Science ®Google Scholar
• EISELT, R., DOMANSKI, T. L., ZIBAT, A., MUELLE R., PRESECAN-SIEDEL, E., HUSTERT, E., ZANGER, U. M., BROCKMOLLER, J., KLENK, H.-P., MEYER, U. A., KHAN, K. K., HE, Y.-Q., HALBERT, J. R. and WOJNOWSKI, L., 2001, Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics, 11, 447–458.
   Google Scholar
• EKINS, S., BRAVI, G., WIKEL, J. H. and WRIGHTON, S. A., 1999, Three-dimensional quantitative structure—activity relationship analysis of cytochrome P450 3A4 substrates. Journal of Pharmacology and Experimental Therapeutics, 291, 424–433.
   PubMed Web of Science ®Google Scholar
• EKINS, S., DE GROOT, M. J. and JONES, J. P., 2001, Pharmacophore and three-dimensional quantitative structure—activity relationship methods for modeling cytochrome P450 active sites. Drug Metabolism and Disposition, 29, 936–944.
   PubMed Web of Science ®Google Scholar
• EVANS, W. E. and RELLING, M. V., 1999, Pharmacogenomics: translating functional genomics into rational therapeutics. Science, 286, 487–491.
   PubMed Web of Science ®Google Scholar
• FRASER, D. J., HE, Y. Q., HARLOW, G. R. and HALBERT, J. R., 1999, Use of chimeric enzymes and site-directed nutagenesis for identification of three key residues responsible for differences in steroid hydroxylation between canine cytochromes P450 3Al2 and 3A26. Molecular Pharmacology, 55, 241–247.
   PubMed Web of Science ®Google Scholar
• GORSKI, J. C., HALL, S. D., JONES, D. R., VAN DEN BRANDEN, M. and WRIGHTON, S. A., 1994, Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochemical Pharmacology, 47, 1643–1653.
   PubMed Web of Science ®Google Scholar
• GOTOH, 0., 1992, Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. Journal of Biological Chemistry, 267, 83–90.
   Google Scholar
• GUENGERICH, F. P., 1995, Human cytochrome P450 enzymes. In P. R. Ortiz de Montellano (ed.), Cytochrome P450 (New York: Plenum), pp. 473–535.
   Google Scholar
• GUENGERICH, F. P., 1999, Cytochrome P450 3A4: regulation and role in drug metabolism. Annual Review of Pharmacology and Toxicology, 39, 1–17.
   PubMed Web of Science ®Google Scholar
• HALBERT, J. R., 1998, Molecular basis of CYP3A4 specificity. In Proceedings of the 5th International ISSX Meeting, Cairns, Australia, vol. 13, p. 7.
   Google Scholar
• HARLOW, G. R. and HALBERT, J. R., 1997, Alanine-scanning mutagenesis of a putative substrate recognition site in human cytochrome P450 3A4. Journal of Biological Chemistry, 272, 5396–5402.
   PubMed Web of Science ®Google Scholar
• HARLOW, G. R. and HALBERT, J. R., 1998, Analysis of human cytochrome P450 3A4 co-operativity: construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics. Proceedings of the National Academy of Sciences, USA, 95, 6636–6641.
   PubMed Web of Science ®Google Scholar
• HE, Y. A., HE, Y. Q., SZKLARZ, G. D. and HALBERT, J. R., 1997, Identification of three key residues in substrate recognition site 5 of human cytochrome P450 3A4 by cassette and site-directed mutagenesis. Biochemistry, 36, 8831–8839.
   PubMed Web of Science ®Google Scholar
• HLAVICA, P. and LEWIS, D. F. V., 2001, Allosteric phenomena in cytochrome P450-catalyzed monooxygenations. European Journal of Biochemistry, 268, 4817–4832.
   PubMedGoogle Scholar
• HONKAKOSKI, P. and NEGISHI, M., 2000, Regulation of cytochrome P450 (CYP) genes by nuclear receptors. Biochemical Journal, 347, 321–337.
   PubMed Web of Science ®Google Scholar
• HOSEA, N. A., MILLER, G. P. and GUENGERICH, F. P., 2000, Elucidation of distinct ligand binding sites for cytochrome P450 3A4. Biochemistry, 39, 5929–5939.
   PubMed Web of Science ®Google Scholar
• INGELMAN-SUNDBERG, M., 2001, Implications of polymorphic cytochrome P450-dependent drug metabolism for drug development. Drug Metabolism and Disposition, 29, 570–573.
   PubMed Web of Science ®Google Scholar
• KENWORTHY, K. E., BLOOMER, J. C., CLARKE, S. E. and HOUSTON, J. B., 1999, CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. British Journal of Clinical Pharmacology, 48, 716–727.
   PubMed Web of Science ®Google Scholar
• KENWORTHY, K. E., CLARKE, S. E., ANDREWS, J. and HOUSTON, J. B., 2001, Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism. Drug Metabolism and Disposition, 29, 1644–1651.
   PubMed Web of Science ®Google Scholar
• KHAN, K. K. and HALBERT, J. R., 2000, Structure—function analysis of human cytochromes P450 3A4 using 7-alkoxycoumarins as active-site probes. Archives of Biochemistry and Biophysics, 373, 335–345.
   PubMed Web of Science ®Google Scholar
• KHAN, K. K., HE, Y. Q. and HALBERT, J. R., 2001, Midazolam metabolism and inactivation of cytochrome P4503A4. In Proceedings of the 12th International Conference on Cytochrome P450, 11–15 September, La Grande Motte, France, p. 85.
   Google Scholar
• KHAN, K. K., HE, Y. Q., CORREIA, M. A. and HALBERT, J. R., 2002a, Differential oxidation of mifepristone by cytochromes P450 3A4 and 3A5: selective inactivation of P450 3A4. Drug Metabolism and Disposition, 30, 985–990.
   PubMed Web of Science ®Google Scholar
• KHAN, K. K., HE, Y. Q., DOMANSKI, T. L. and HALBERT, J. R., 2002b, Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: an evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation. Molecular Pharmacology, 61, 495–506.
   PubMed Web of Science ®Google Scholar
• KUHN, B., JACOBSEN, W., CHRSTIANS, U., BENET, L. Z. and KOLLMAN, P. A., 2001, Metabolism of Sirolimus and its derivative Everolimus by cytochrome P4503A4: insights from docking, molecular dynamics and quantum chemical calculations. Journal of Medicinal Chemistry, 44, 2027–2034.
   PubMed Web of Science ®Google Scholar
• LEEDER, J. S., GAEDIGK, A., Lu, X. and COOK, V. A., 1996, Epitope mapping studies with human anti-cytochrome P450 3A antibodies. Molecular Pharmacology, 49, 234–243.
   PubMed Web of Science ®Google Scholar
• LEWIS, D. F. V., 1996, Cytochromes P450: Structure, Function and Mechanism (London: Taylor & Francis).
   Google Scholar
• LEWIS, D. F. V., 2000, On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics: towards the prediction of human P450 substrate specificity. Biochemical Pharmacology, 60, 293–306.
   PubMed Web of Science ®Google Scholar
• LEWIS, D. F. V., 2001, Guide to Cytochromes P450 Structure and Function (London: Taylor & Francis). LEWIS, D. F. V., 2002, Homology modelling of human CYP2 family enzymes based on the CYP2C5 crystal structure. Xenobiotica, 32, 305–323.
   Google Scholar
• LEWIS, D. F. V., 2003, On the estimation of binding affinity (AGbd) for human P450 substrates based on Km and KD values. Current Drug Metabolism, 4, 331–340.
   PubMed Web of Science ®Google Scholar
• LEWIS, D. F. V. and DICKINS, M., 2002, Substrate SARs in human P450s. Drug Discovery Today, 17, 918–925.
   Google Scholar
• LEWIS, D. F. V., EDDERSHAW, P. J., DICKINS, M., TARBIT, M. H. and GOLDFARB, P. S., 1998, Structural determinants of P450 substrate specificity, binding affinity and catalytic rate. Chemico-Biological Interactions, 115, 175–199.
   Google Scholar
• LEWIS, D. F. V., EDDERSHAW, P. J., GOLDFARB, P. S. and TARBIT, M. H., 1996, Molecular modelling of CYP3A4 from an alignment with CYP102: identification of key interactions between putative active site residues and CYP3A-specific chemicals. Xenobiotica, 26, 1067–1086.
   Google Scholar
• LEWIS, D. F. V., Mom, S. and DICKINS, M., 2001, Quantitative structure—activity relationships (QSARs) within substrates of human cytochromes P450 involved in drug metabolism. Drug Metabolism and Drug Interactions, 18, 221–242.
   Google Scholar
• LEWIS, D. F. V., Mom, S. and DICKINS, M., 2002, Structure—activity relationships for human cytochrome P450 substrates and inhibitors. Drug Metabolism Reviews, 34, 69–82.
   Google Scholar
• LI, A. P., KAmiNsio, D. L. and RASMUSSEN, A., 1995, Substrates of human hepatic cytochrome P450 3A4. Toxicology, 104, 1–8.
   PubMed Web of Science ®Google Scholar
• Lu, P., LIN, Y., RODRIGUES, A. D., RUSHMORE, T. H., BAILLIE, T. A. and SHOU, M., 2001, Testosterone, 7-benzyloxyquinoline and 6-benzyloxy-4-trifluoromethyl coumarin bind to different domains with the active site of cytochrome P450 3A4. Drug Metabolism and Disposition, 29, 1473–1479.
   PubMed Web of Science ®Google Scholar
• PASCUSSI, J.-M., DROCOURT, L., FABRE, J.-M., MAUREL, P. and VILAREM, M.-J., 2000, Dexamethasone induces pregnane X receptor and retinoid X receptor-a expression in human hepatocytes: synergistic increase of CYP3A4 induction by pregnane X receptor activators. Molecular Pharmacology, 58, 361–372.
   PubMed Web of Science ®Google Scholar
• PELKONEN, 0., MAENPAA, J., TAAVITSAINEN, P., RAUTIO, A. and RAUNIO, H., 1998, Inhibition and induction of human cytochrome P450 (CYP) enzymes. Xenobiotica, 28, 1203–1253.
   Google Scholar
• RENDIC, S., 2002, Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metabolism Reviews, 34, 83–448.
   PubMed Web of Science ®Google Scholar
• RENDIC, S. and DICARLO, F. J., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers and inhibitors. Drug Metabolism Reviews, 29, 413–580.
   PubMed Web of Science ®Google Scholar
• RENWICK, A. B., LEWIS, D. F. V., FULFORD, S., SURRY, D., WILLIAMS, N., WORBOYS, P. D., CAI, X., WANG, R. W., PRICE, R. J., LAKE, B. G. and EVANS, D. C., 2001, Metabolism of 2,5-bis(trifluoro-methyl)-7-benzyloxy-4-trifluoromethyl coumarin by human hepatic CYP isoforms: evidence for selectivity towards CYP3A4. Xenobiotica, 31, 187–204.
   Google Scholar
• ROUSSEL, F., KHAN, K. K. and HALPERT, J. R., 2000, The importance of SRS-1 residues in catalytic specificity of human cytochrome P450 3A4. Archives of Biochemistry and Biophysics, 374, 269–278.
   PubMed Web of Science ®Google Scholar
• SATA, F., SAPONE, A., ELIZONDO, G., STOCKER, P., MILLER, V. P., ZHENG, W., RAUNIO, H., CRESPI, C. L. and GONZALEZ, F. J., 2000, CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clinical Pharmacology and Therapeutics, 67, 48–56.
   PubMed Web of Science ®Google Scholar
• SHOU, M., GROGAN, J., MANCEWICZ, J. A., KRAUSZ, K. W., GONZALEZ, F. J., GELBOIN, H. V. and KORZEKWA, K. R., 1994, Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry, 33, 6450–6455.
   PubMed Web of Science ®Google Scholar
• SHOU, M., MEI, Q., ETTORE, M. W., DAI, R., BAILLIE, T. A. and RUSHMORE, T. H., 1999, Sigmoidal kinetic model for two cooperative substrate-bindings sites in a cytochrome P450 3A4 active site: an example of the metabolism of diazepam and its derivatives. Biochemical Journal, 340, 845–853.
   PubMed Web of Science ®Google Scholar
• SINGH, S. B., SHEN, L. Q., WALKER, M. J. and SHERIDAN, R. P., 2003, A model for predicting likely sites of CYP3A4-mediated metabolism in drug-like molecules. Journal of Medicinal Chemistry, 46, 1330–1336.
   PubMed Web of Science ®Google Scholar
• STEVENS, J. C., DOMANSKI, T. L., HARLOW, G. R., WHITE, R. B., ORTON, E. and HALPERT, J. R., 1999, Use of the cytochrome P450 3A4 structure/function analysis. Journal of Pharmacology and Experimental Therapeutics, 290, 594–602.
   PubMed Web of Science ®Google Scholar
• SZKLARZ, G. D. and HALPERT, J. R., 1997, Molecular modeling of cytochrome P450 3A4. Journal of Computer-Aided Molecular Design, 11, 265–272.
   PubMed Web of Science ®Google Scholar
• SZKLARZ, G. D. and HALPERT, J. R., 1998, Molecular basis of P450 inhibition and activation. Drug Metabolism and Disposition, 26, 1179–1184.
   PubMed Web of Science ®Google Scholar
• THUMMEL, K. E. and WILKINSON, G. R., 1998, In vitro and in vivo drug interactions involving human CYP3A. Annual Review of Pharmacology and Toxicology, 38, 389–430.
   PubMed Web of Science ®Google Scholar
• TOMLINSON, E. S., LEWIS, D. F. V., MAGGS, J. L., PARK, B. K. and BACK, D. J., 1997, In vitro metabolism of side-chain cleaved dexamethasone (9F-A) is CYP3A4 mediated: rationalization of CYP3A4 and CYP17 (17,20 lyase) involvement in dexamethasone metabolism in vitro based on molecular modelling studies. Biochemical Pharmacology, 54, 605–611.
   Google Scholar
• UENG, Y.-F., KUWABARA, T., CHUN, Y.-J. and OUENGERICH, F. P., 1997, Cooperativity in oxidations catalysed by cytochrome P450 3A4. Biochemistry, 36, 370–381.
   PubMed Web of Science ®Google Scholar
• WANG, H., DICK, R., YIN, H., LICAD-COLES, E., KROETZ, D. L., SZKLARZ, G., HARLOW, G., HALPERT, J. R. and CORREIA, M. A., 1998, Structure—function relationships of human liver cytochromes P450 3A: aflatoxin B1 metabolism as a probe. Biochemistry, 37, 12536–12545.
   Google Scholar
• WILLIAMS, J. A., RING, B. J., CANTRELL, V. E., JONES, D. R., ECKSTEIN, J., RUTERBORIES, K., HAMMAN, H. A., HALL, S. D. and WRIGHTON, S. A., 2002, Comparative metabolic capabilities of CYP3A4, CYP3A5 and CYP3A7. Drug Metabolism and Disposition, 30, 883–891.
   PubMed Web of Science ®Google Scholar
• WILLIAMS, P. A., COSME, J., SRIDHAR, V., JOHNSON, E. F. and McREE, D. E., 2000, Mammalian cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Molecular Cell, 5, 121–131.
   PubMed Web of Science ®Google Scholar
• WRIGHTON, S. A., SCHEUTZ, E. G., THUMMEL, K. E., SHEN, D. D., KORZEKWA, K. R. and WATKINS, P. B., 2000, The human CYP3A subfamily: practical considerations. Drug Metabolism Reviews, 32, 339–361.
   PubMed Web of Science ®Google Scholar
• XUE, L., WANG, H. F., WANG, Q., SZKLARZ, G. D., DOMANSKI, T. L., HALPERT, J. R. and CORREIA, M. A., 2001, Influence of P4503A4 SRS-2 residues on cooperatively and/or regioselectivity of aflatoxin B1 oxidation. Chemical Research in Toxicology, 14, 483–491.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI, H. and SHIMADA, T., 1997, Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9 and 3A4 in human liver microsomes. Archives of Biochemistry and Biophysics, 346, 161–169.
   PubMed Web of Science ®Google Scholar